Prospects for AstraZeneca PLC's ovarian cancer drug Lynparza (olaparib) have been boosted strongly by positive headline data from the Phase III SOLO-2 trial studying the inhibitor of poly ADP–ribose polymerase (PARP) as a maintenance therapy in BRCA-mutated second-line ovarian cancer.
The drug – which AstraZeneca once shelved due to uncertain prospects during development - showed a clinically and statistically significant benefit on progression-free survival (PFS) over placebo, positioning Lynparza for an